Press Releases

Emplicure has been selected as a winner in the regional Scandinavian pitch competition

Emplicure was selected as one of the bests Scandinavian startups in the European HealthCatapult (EHC) programme. They will now be one of the companies to represent EIT Health Scandinavia in the semifinals in Europe. In the first selection round held in Stockholm the 27th of May Susanne Bredenberg, CEO of Emplicure, was pitching in front of an experienced jury.

" We had an exciting day in Stockholm, both presenting our business, as well as listen to other promising start-up companies. I feel proud of being one of the companies to present Scandinavia in the semifinals and I'm really looking forward to present how we will develop the next generation of pain treatments", says Susanne Bredenberg.

In the semi-final competition in the Netherlands the 24th to the 26th of September the top Biotech start-ups from all EIT Health regions participate.

"For us this is really a good timing since we now look for new investments to take the next step and initiate clinical studies with one our products", says Susanne Bredenberg.

The final will be at the EIT Health year Summit in Paris the 2nd to the 3rd of December with approximately around 500 attendees.


Emplicure AB announces today that the Nomination Committee for the annual general shareholders meeting (AGM) in April 2022 is formed. The Nomination Committee consists of representatives nominated by the three largest shareholders per the last bank-day in the third quarter, as well as the Chairman of the Board. Emplicure's three largest shareholders, also the founders, have agreed to vote as one, in order to to give preference for more shareholders.


Emplicure AB has received issue notification from the US Patent and Trademark Office that a formal approval of the inhalation platform of pharmaceuticals will be issued on December 21, 2021.


Erik Magnusson appointed new Chief Financial Officer (CFO) in Emplicure AB.


Following this summer's new share issue and subsequent IPO, we are well equipped. The focus of the third quarter has been on shifting up, and driving the development of the company's two main projects; Empli03, our drug candidate for chronic pain, and Amp01, our oral tobacco-free nicotine product in the form of dry, white pouches as a consumer product. Both projects are developed on our own bioceramic and patented technologies and platforms.


Anna-Lena Nicolson, CFO och medlem i ledningsgruppen i Emplicure AB (publ), har idag beslutat att lämna sitt uppdrag. Anna-Lena kommer att kvarstå som CFO till och med den 31 december 2021. Processen med att rekrytera hennes ersättare har inletts.


Emplicure AB (publ) har anställt Anna Franzén som Sr. Manager Clinical Projects för att driva och utveckla bolagets kliniska projekt.


Emplicure AB (publ) meddelar idag att pantentmyndigheten i USA har utfärdat ett så kallat "Notice of Allowance" avseende Emplicures patentansökan för "Inhalation av läkemedel".


Som tidigare kommunicerats har Emplicure AB (publ) ("Emplicure" eller "Bolaget") genomfört en unitemission av aktier och teckningsoptioner av serie TO1 ("Teckningsoptionerna") i samband med en börsnotering på Nasdaq First North Growth Market. Första dag för handel med Teckningsoptionerna på Nasdaq First North Growth Market är den 19 juli 2021.



Do you want to know more?

Contact us today.